Scientific Resources INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in a Murine Syngeneic Tumor Model (Poster presented at SITC 2024) 8.5 MB The Tumor-Activated IL-12 Prodrug WTX-330 Expanded and Activated Tumor Infiltrating Lymphocytes and Caused Tumor Regression in Patients with Refractory Solid Tumors: Interim Data From an Ongoing Phase 1 Study (Poster presented at SITC 2024) 6 MB A phase 1/1b trial of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy (Poster presented at ASCO 2024) 3.8 MB Development of Conditionally Active IL-10 INDUKINE™ Molecules for the Treatment of Inflammatory Bowel Disease (Poster presented at AAI 2024) 1.9 MB Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models (Poster presented at AACR 2024) 2.6 MB WTX-712, a conditionally active IL-21 INDUKINE™ molecule, induces a strong anti-tumor phenotype through a differentiated mechanism (Poster presented at AACR 2024) 3 MB A Phase 1/1b Study of the Tumor-Activated IL-2 Prodrug WTX-124 Alone or in Combination with Pembrolizumab in Patients with Immunotherapy-Sensitive Locally Advanced or Metastatic Solid Tumors (Presented as a poster at SITC 2023 Annual Meeting) 5.3 MB Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) and IL-2 (WTX-124) INDUKINETM Molecules (Presented as a poster at SITC 2023 Annual Meeting) 4.6 MB Development of WTX-712, a Conditionally Activated IL-21 INDUKINETM Molecule for the Treatment of Cancer (Presented as a poster at SITC 2023 Annual Meeting) 2.4 MB The Combination of ACT and INDUKINETM Therapy Leads to Improved Antitumor Immunity in Solid Tumors (Presented as a poster at SITC 2023 Annual Meeting) 1.8 MB Current page 1 Page 2 Page 3 Next page › Last page »
INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in a Murine Syngeneic Tumor Model (Poster presented at SITC 2024) 8.5 MB
The Tumor-Activated IL-12 Prodrug WTX-330 Expanded and Activated Tumor Infiltrating Lymphocytes and Caused Tumor Regression in Patients with Refractory Solid Tumors: Interim Data From an Ongoing Phase 1 Study (Poster presented at SITC 2024) 6 MB
A phase 1/1b trial of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy (Poster presented at ASCO 2024) 3.8 MB
Development of Conditionally Active IL-10 INDUKINE™ Molecules for the Treatment of Inflammatory Bowel Disease (Poster presented at AAI 2024) 1.9 MB
Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models (Poster presented at AACR 2024) 2.6 MB
WTX-712, a conditionally active IL-21 INDUKINE™ molecule, induces a strong anti-tumor phenotype through a differentiated mechanism (Poster presented at AACR 2024) 3 MB
A Phase 1/1b Study of the Tumor-Activated IL-2 Prodrug WTX-124 Alone or in Combination with Pembrolizumab in Patients with Immunotherapy-Sensitive Locally Advanced or Metastatic Solid Tumors (Presented as a poster at SITC 2023 Annual Meeting) 5.3 MB
Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) and IL-2 (WTX-124) INDUKINETM Molecules (Presented as a poster at SITC 2023 Annual Meeting) 4.6 MB
Development of WTX-712, a Conditionally Activated IL-21 INDUKINETM Molecule for the Treatment of Cancer (Presented as a poster at SITC 2023 Annual Meeting) 2.4 MB
The Combination of ACT and INDUKINETM Therapy Leads to Improved Antitumor Immunity in Solid Tumors (Presented as a poster at SITC 2023 Annual Meeting) 1.8 MB
